The topic of this article may not meet Wikipedia's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.Find sources: "N1-Methyl-lysergic acid diethylamide" – news · newspapers · books · scholar · JSTOR (April 2015) (Learn how and when to remove this template message)
N1-Methyl-lysergic acid diethylamide
Clinical data
Other namesMLD-41; N1-Methyl-Lysergic Acid Diethylamide
Routes of
administration		Oral
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal
Identifiers
  • (8β)-N,N-Diethyl-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H27N3O
Molar mass337.467 g·mol−1
3D model (JSmol)
  • O=C(N(CC)CC)[C@@H]3/C=C2/c4cccc1c4c(cn1C)C[C@H]2N(C3)C
  • InChI=1S/C21H27N3O/c1-5-24(6-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22(18)3)11-19(17)23(4)13-15/h7-10,12,15,19H,5-6,11,13H2,1-4H3/t15-,19-/m1/s1 checkY
  • Key:VQZYKSWQIQANKB-DNVCBOLYSA-N checkY
  (verify)

N1-Methyl-lysergic acid diethylamide (MLD-41) is a derivative of LSD that has about one-third the psychoactive effects. It has been studied in cross-tolerance of LSD.[1]

Metabolism of other 1-methylated-ergoloids to their secondary amine derivatives has been frequently noted in mammals.[2]

References

  1. ^ Abramson HA, Rolo A, Sklarofsky B, Stache J (January 1960). "Production of cross-tolerance to psychosis-producing doses of lysergic acid diethylamide and psilocybin". The Journal of Psychology. 49 (1): 151–4. doi:10.1080/00223980.1960.9916396.
  2. ^ Müller-Schweinitzer E, Tapparelli C (March 1986). "Methylergometrine, an active metabolite of methysergide". Cephalalgia: An International Journal of Headache. 6 (1): 35–41. doi:10.1046/j.1468-2982.1986.0601035.x. PMID 3698092. S2CID 5778173.


Categories